Delivery Order SPE2DB22D1017-SPE2DB25FG7WR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,704.73 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply framework with the federal government. The product will be performed and delivered from AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a $11,893.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Orencia 125 mg/ml syringes. This non-set-aside competitive award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a $5,590.59 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract is not set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be executed from the contractor's location in...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) for Orencia 125 mg/mL syringes valued at $8,646.31. The award was made on July 31, 2025, with an ultimate completion date of August 1, 2025, under firm fixed pricing with no set-aside designation. This delivery order represents a competitively awarded transaction processed through the company's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Orencia 125 mg/ml syringes valued at $14,495.04. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and utilizes firm fixed pricing. The place of...
- The Defense Logistics Agency awarded a $17,488.86 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Orencia ClickJect 125 mg/mL, a pharmaceutical product used in the treatment of rheumatoid arthritis and other autoimmune conditions. This non-set-aside delivery order is scheduled for ultimate completion on August 4, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orencia 250 mg vials, with a contract ceiling value of $14,863.40. The award, issued on July 30, 2025, is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025. This non-competitive set-aside award represents a specific pharmaceutical procurement from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place...
- The Defense Logistics Agency awarded a delivery order valued at $4,362.12 to AmerisourceBergen Drug Corp for the supply of Orencia 250 mg vials. This firm fixed price contract, issued on August 22, 2025, represents a non-set-aside award with an ultimate completion date of August 25, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Orencia is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $10,782.12 to AmerisourceBergen Drug Corp for Orencia ClickJect 125 mg/mL, a pharmaceutical product used in rheumatoid arthritis treatment. This competitively awarded, firm fixed-price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,815.75 to AmerisourceBergen Drug Corp for Orencia ClickJect 125 mg/ml, a pharmaceutical product used in the treatment of rheumatoid arthritis and other autoimmune conditions. This firm fixed price delivery order, issued on August 12, 2025, with ultimate completion by August 13, 2025, represents a single procurement under the company's larger indefinite delivery contract with DLA. The award was made on a competitive, non-set-aside...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7WRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Orencia 125 mg/ml syringes with a ceiling value of $8,140.49. This firm fixed-price delivery order represents a non-set-aside competitive award and is expected to be completed by July 23, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, and medical supplies to military healthcare systems and other federal agencies. Orencia, a biologic immunosuppressant, is consistent with the company's portfolio of specialty pharmaceutical products delivered through this strategic contract vehicle to support Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 7/22/25 |